How FDA Commissioner Scott Gottlieb Would Affect Supplement Regs

Adjust Comment Print

Gottlieb is a venture partner in New Enterprise Associates, which invests chiefly in early-stage companies in information technology, medicine, and life sciences. Gottlieb's job will be to cut the red tape at the FDA, which regulates everything from pharmaceuticals to cosmetics.

President Donald Trump is poised to choose conservative Doctor Scott Gottlieb to head the Food and Drug Administration, according to a White House official. He also served as FDA deputy commissioner under President George W. Bush from 2005 to 2007. "He is seen as a strong supporter of that industry and has championed deregulation".

Gottlieb's views on speeding up the review of generic products, and increasing generic competition, have been well-received, Alexander said, adding that Gottlieb's extensive industry experience is both "an asset and a liability". But while he delivered the comments with the bravado and populist rhetoric that have become the hallmark of his discourse, both in the public and on social media, he surprised a number of political and media observers alike when he announced on March 10, 2017 his intention to nominate Scott Gottlieb, MD, as the next commissioner of the FDA.

The President's choice still has to win the backing of the Senate, and the confirmation process will kick off with a hearing in front of the Senate Health, Education, Labor and Pensions (HELP) committee, now controlled by Republicans. He is now assistant professor at New York University School of Medicine.

"He'd clearly need to divest his own stock and resign from the boards", Diana Zuckerman, president of the National Center for Health Research, told STAT. In fact, clinicians at the front lines caring for patients and populations affected by these diseases have for years been calling for balanced reforms that allow for novel products to come online faster-importantly, however, without comprising safety standards and while still keeping a watchful eye on the companies that manufacture them. "His experience as FDA deputy commissioner and in other key FDA positions will enable him to quickly step into this important role after his confirmation. The Senate must reject the nomination and demand a nominee who is better suited to protect public health", according to the statement.